SLS — SELLAS Life Sciences Group, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1390478 ·
Last close
$7.83
Market Cap
$1.54B
52W High
$9.51
52W Low
$3.95
ADV30
9,477,883
Next earnings
2026-08-11
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -9,252,000 | -8,407,000 | 114,177,000 | 107,097,000 | 6,765,000 |
| Dec 2025 | 0 | — | -8,255,000 | -7,658,000 | 78,345,000 | 71,793,000 | 7,474,000 |
| Sep 2025 | 0 | — | -7,083,000 | -6,791,000 | 51,555,000 | 44,320,000 | 5,925,000 |
| Jun 2025 | 0 | — | -6,873,000 | -6,601,000 | 32,305,000 | 25,297,000 | 6,156,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-28,165,000
Investing CF
$0
Financing CF
$106,865,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.25
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-283,395,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-31,463,000
Pretax Income TTM
$-29,457,000
Interest Exp TTM
—
Analysts
2
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -28,274,000 | -26,863,000 | 78,345,000 | 7,474,000 | — | -28,389,000 |
| Dec 2024 | 0 | -31,513,000 | -30,881,000 | 19,432,000 | 9,967,000 | — | -35,402,000 |
| Dec 2023 | 0 | -37,869,000 | -37,340,000 | 6,219,000 | 14,195,000 | — | -31,410,000 |
| Dec 2022 | 1,000,000 | -31,950,000 | -41,301,000 | 20,943,000 | 16,092,000 | — | -23,809,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$16,690,000
NetIncome TTM
$-30,482,000
OpCashFlow TTM
$0
Assets (Latest)
$19,432,000
Forward EPS
$-0.15
Max Pain — expiry 2026-06-18
max pain strike: $7.00 · spot: $7.73 · call oi: 36,694 · put oi: 16,270
Expected Move to 2026-06-18:
±$0.80
(10.35%) —
implied range
$6.93 –
$8.53
· ATM straddle on $7.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PRGO | PERRIGO Co plc | $1.52B | $10.99 | — |
| PVLA | PALVELLA THERAPEUTICS, INC. | $1.56B | $108.81 | — |
| PGEN | PRECIGEN, INC. | $1.59B | $4.45 | — |
| CAPR | CAPRICOR THERAPEUTICS, INC. | $1.49B | $25.80 | — |
| GENB | Generate Biomedicines, Inc. | $1.59B | $12.38 | — |
News headlines (Yahoo Finance, 1h cache)
Exploring 3 High Growth Tech Stocks in US Market
2026-06-15 11:39 · Yahoo
SLS Stock Slides Premarket: Traders Brace For Key Arbitration Ruling In GPS China Payment Dispute
2026-06-05 08:51 · Yahoo
SLS CEO Angelos Stergiou Highlights Extended Capital Runway To Pursue Key Milestones, Growth Opportunities – A Look At The Important Numbers
2026-06-02 14:54 · Yahoo
Jim Cramer on SELLAS: “It’s a Great Spec”
2026-06-01 17:33 · Yahoo
SELLAS Life Sciences Group (SLS) Is Up 21.4% After REGAL Nears Topline Readout And Cramer Endorsement
2026-05-29 20:02 · Yahoo
SLS Stock Rises Overnight: Traders Rally Behind Jim Cramer's 'Two Thumbs Up' Call Ahead Of Key AML Readout
2026-05-29 04:40 · Yahoo
SLS Stock Extends Rally Overnight: CEO Says ‘Bullish’ Leukemia Data Could Drive NCCN Recognition For GPS
2026-05-28 03:30 · Yahoo
SLS Stock Surges Toward Fifth Weekly Rise: CEO Touts GPS As Lifeline For Elderly Patients As Cancer Summit Looms
2026-05-27 03:21 · Yahoo
SLS Stock Heads For Its Best Month This Year Ahead Of Key AML Trial Readout
2026-05-26 11:26 · Yahoo
SLS Stock Tanks Hard: Retail Traders Blame Warrant Holders, 'Flippers' Cashing Out Before AML Catalyst
2026-05-22 03:54 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.